Hereditary Neuromuscular Diseases. Part 3. Muscular Dystrophies: Pathogenesis, Diagnosis and Attempts of Trial Treatments
https://doi.org/10.30629/2658-7947-2020-25-2-5-11
Abstract
Membrane theory of muscle weakness in hereditary muscular dystrophy was described with accent of predominated Ca2+ ions in skeletal muscle due to destruction of the sarcolemma and other membranes of the different organelles of the skeletal muscle. Showed the role of CT, MRI and phosphorus NMR-spectroscopy as well as the noninvasive the analysis cell-free fetus DNA in maternal plasma for prenatal diagnostic of muscular dystrophies. The different a trial attempts of treatment of muscular dystrophy was described.
About the Authors
V. M. Kazakov
Department of Neurology First Pavlov State Medical University; State Medical University, Russia Department of Neuromuscular Diseases, City Hospital 2
Russian Federation
St. Petersburg
Russian Federation
St. Petersburg
A. A. Skoromets
Department of Neurology First Pavlov State Medical University
Russian Federation
St. Petersburg
Russian Federation
St. Petersburg
D. I. Rudenko
Department of Neurology First Pavlov State Medical University; State Medical University, Russia Department of Neuromuscular Diseases, City Hospital 2
Russian Federation
St. Petersburg
Russian Federation
St. Petersburg
T. R. Stuchevskaya
Department of Neurology First Pavlov State Medical University; State Medical University, Russia Department of Neuromuscular Diseases, City Hospital 2
Russian Federation
St. Petersburg
Russian Federation
St. Petersburg
V. O. Kolynin
Department of Neurology First Pavlov State Medical University; State Medical University, Russia Department of Neuromuscular Diseases, City Hospital 2
Russian Federation
St. Petersburg
Russian Federation
St. Petersburg
References
1. Duboc D., Jehenson P., Tran Dinh S., et al. Phosphorus NMR spectroscopy study of muscular enzyme deficiency involving glycogenosis and glycolysis. Neurology. 1987;37:663–671.
2. Kazakov V.M., Rudenko D.I., Skoromets A.A. Facioscapulo-humeral muscular dystrophy and her connection with facio-scapulo-peroneal muscular dystrophy. History, clinical, genetics and differential diagnosis. Sunct-Petersburg: Polytechnica. 2008;374. (In Russian).
3. Kazakov V., Kolynin V., Rudenko D., Pozdnyakov A. MRI of lower limb muscles in patients with 4q35-linked FSLD2. Oxford Symposium on Muscle Disease. Oxford, UK. 2007;5.
4. Kolynin V.O. Magnit-resonance tomographic (MRT) of skeletal muscles in patients with autosomal dominant facio-scapulo-humeral muscular dystrophy linked with chromosome 4q35. Thesis, SPb. 2007;174. (In Russian).
5. Bakker E., van Ommen G.J.B. Duchenne and Becker muscular dystrophy (DMD and BMD) In: Neuromuscular Disorders: Clinical and molecular genetics. (Ed. A.E.H. Emery), Chichester: Wiley. 1998;59–85.
6. Upadhyaya M., MacDonald M., Ravine D. Noninvasive prenatal diagnosis for facioscapulohumeral muscular dystrophy (FSHD). Prenat. Diagn. 1999;19(10):959–965.
7. Imran Rafi, Lyn Chitty. Noninvasive the analysis cell-free fetus DNA in maternal plasma and non-invasive prenatal diagnosis. Br. J. Gen. Pract. 2009;59 (562):146–148.
8. Sacconi S., Trevisson E., Salviati L. et al. Coenzyme Q10 is frequently reduced in muscle in patients with mitochondrial myopathy. Neuromuscul. Disord. 2010;20(1):44–48.
9. Buyse G.M., Goemans M., van den Nauwe et al. Idebenon as a novel therapeutic approach for Duchenne muscular dystrophy. Results from a 12 months, double-blind, randomized placebocontrolled trial. Neuromusul. Disord. 2011;21 (6):396–405.
10. Griggs R.C., Herr B.E, Eagle M. et al. Equipoise concerning corticosteroid use in boys with Duchenne muscular dystrophy: persistent wide variation in practice. (Abstract). Neuromuscul. Disord. 2008;18(9–10):824.
11. Angelini C., Peterle E. Old and new therapeutic developments in steroid treatment in Duchenne muscular dystrophy. Acta Myol. 2012;31:9–20.
12. Wong-Kisiel L.C., Kuntz N.L. Two siblings with limb-girdle dystrophy type 2E responsive to deflazacort. Neuromuscul. Disord. 2010;20(2):122–124.
13. Hoffman E.P, Riddlec V., Maxime A. et al. Phase 1 trial of vamorolone, a first-in-class steroid, shows improvements in side effects via biomarkers bridged to clinical outcomes. Steroid. 2018;134:43–52.
14. Munzur A.Y. Glucocorticoid corticosteroid for Duchenne muscular dystrophy. Cochrane Detabase Syst. Rev. 2008;23(1):3725.
15. Suri, Valdia. Glucocorticoid regulation of brain-derived neurotrophic factor: Relevance to hippocampal structural and functional plasticity. Neuroscience. 2013;239:196–213.
16. Merlini L., Angellini A., Tiepolo T. et al. Cyclosporine A corrects mitochondrial dysfunction and muscle apoptosis in patients with collagen VI myopathies. Proc. Nat. Sci. 2008;105;(9–10):52255229.
17. Merlini L., Bernardi P. Therapy of collagen VI-related myopathy (Bethlem and Ulrich). Neurotherapeutics. 2008;5:613–618.
18. Politano L., Nigro G., Nigro V. et al. Gentamicin administration in Duchenne patients with premature stop codon. Preliminary results. Acta Myol. 2003;XXII(1):11–14.
19. van der Kooi E.L., Vogels O.J., van Asseldonk R.J. et al. Strength training and albuterol in facioscapulohomeral muscular dystrophy. Neurology. 2004;24:702–708.
20. Harcourt L.J., Schertzer J.D., Ryall J.G, Lynch G.S. Lower dose formoterol administration improves muscle function in dystrophic mdx mice without increasing fatigue. Neuromuscul Disord. 2007;17:47–55.
21. Patel K., Macharia R, Amthor H. Molecular mechanisms involving IGF-1 and myostatin to induce muscle hypertrophy as a therapeutic strategy for Duchenne muscular dystrophy. Acta Myol. 2005;XXIV(3):230–241.
22. Scheuerbrandt G. Fourth round table conference in Monaco on 15 January 2005: Regulation of muscle growth, a therapeutic issue for Duchenne muscular dystrophy. Acta Myol. 2005;XXIV (1):25–35.
23. Tsuchida K. Myostatin inhibition by a follistatin-derived peptide ameliorates the pathophysiology of MD model mice. Acta Myol. 2008;XXVII:14–18.
24. Ohsawa Y., Okada T., Kuga A. et al. Caveolin-3 regulates myostatin signaling — Mini-review. Acta Myol. 2008;XXVII:19–24.
25. Morgan J.E. Stem cells to treat muscular dystrophies. Acta Myol. 2005;XXIV(3):181–183.
26. Mouli V., Aamiri A, Perie S et al. Myoblast transfer therapy. Is there any light at the end of the tunnel? Acta Myol. 2005;XXIV(2):128–133.
27. Vilqin J.T. Myoblast transplantation: clinical trials and perspectives. Mini-review. Acta Myol. 2005;XXIV(2):119–127.
28. Morosetti R., Girardo T., Broccoloni A. et al. Mesoangioblasts from FSHMD display in vivo a variable myogenic ability predictable by their in vitro behavior. Cell Transplant. 2010;20(8):1299–313.
29. Bertoni C. Oligonucleotide-mediated gene editing for neuromuscular disorders. Acta Myol. 2005;XXIV:194–201.
30. Scheuerbrandt G. Exon Skipping with U7 gene transfer. Acta Myol. 2006;XXV:40–42.
31. Yokoto T., Duddy W., Partridge T. Optimizing exon skipping therapies for DMD. Acta Myol. 2007;XXVI(3):179–84.
32. Muntoni F. The development of antisense oligonucleotide therapies for Duchenne muscular dystrophy. Neuromuscul. Disord. 2010;20(5):355–362.
Review
For citations:
Kazakov V.M., Skoromets A.A., Rudenko D.I., Stuchevskaya T.R., Kolynin V.O. Hereditary Neuromuscular Diseases. Part 3. Muscular Dystrophies: Pathogenesis, Diagnosis and Attempts of Trial Treatments. Russian neurological journal. 2020;25(2):5-11. (In Russ.) https://doi.org/10.30629/2658-7947-2020-25-2-5-11
Views:
776
Email this article 